key: cord-0696928-9foasug4
authors: Romero, I. M.; Marcolino, M. S.; Pires, M. C.; Ramos, L. E. F.; Silva, R. T.; Guimaraes Junior, M. H.; Oliveira, I. J. R. d.; Carvalho, R. L. R. d.; Nunes, A. G. S.; Barros, A. L. R. M. d.; Scotton, A. L. B. A.; Madureira, A. A. C.; Farace, B. L.; Carvalho, C. A. d.; Rodrigues, F. d.; Anschau, F.; Botoni, F. A.; Nascimento, G. F.; Duani, H.; Guimaraes, H. C.; Alvarenga, J. C. d.; Moreira, L. B.; Zandona, L. B.; Almeida, L. F. d.; Oliveira, L. M.; Kopittke, L.; Castro, L. C. d.; Santos, L. E. A.; Cabral, M. A. d. S.; Ferreira, M. A. P.; Sampaio, N. d. C. S.; Oliveira, N. R. d.; Francisco, S. C.
title: Chagas disease and SARS-CoV-2 coinfection does not lead to worse in-hospital outcomes: results from the Brazilian COVID-19 Registry
date: 2021-03-26
journal: nan
DOI: 10.1101/2021.03.22.21254078
sha: d17404ab09041233a8397b90c2652419b266b35a
doc_id: 696928
cord_uid: 9foasug4

Objective: Chagas disease (CD) continues to be a major public health burden in Latina America, where co-infection with SARS-CoV-2 can occur. However, information on the interplay between COVID-19 and Chagas disease is lacking. Our aim was to assess clinical characteristics and in-hospital outcomes of patients with CD and COVID-19, and to compare it to non-CD patients. Methods: Patients with COVID-19 diagnosis were selected from the Brazilian COVID-19 Registry, a prospective multicenter cohort, from March to September, 2020. CD diagnosis was based on hospital record at the time of admission. Study data were collected by trained hospital staff using Research Electronic Data Capture (REDCap) tools. Genetic matching for sex, age, hypertension, DM and hospital was performed in a 4:1 ratio. Results: Of the 7,018 patients who had confirmed infection with SARS-CoV-2 in the registry, 31 patients with CD and 124 matched controls were included. Overall, the median age was 72 (64.-80) years-old and 44.5% were male. At baseline, heart failure (25.8% vs. 9.7%) and atrial fibrillation (29.0% vs. 5.6%) were more frequent in CD patients than in the controls (p<0.05 for both). C-reactive protein levels were lower in CD patients compared with the controls (55.5 [35.7, 85.0] vs. 94.3 [50.7, 167.5] mg/dL). Seventy-two (46.5%) patients required admission to the intensive care unit. In-hospital management, outcomes and complications were similar between the groups. Conclusions: In this large Brazilian COVID-19 Registry, CD patients had a higher prevalence of atrial fibrillation and chronic heart failure compared with non-CD controls, with no differences in-hospital outcomes. The lower C-reactive protein levels in CD patients require further investigation.

What is already known about this subject?

• Preexisting cardiovascular disease enhances vulnerability to COVID-19.

• Co-infection with SARS-CoV-2 and T.cruzi can occur in patients living in areas in which both infections are epidemic.

• Despite a higher frequency of chronic heart failure and atrial fibrillation, our findings do not suggest that co-infection with T.cruzi and SARS-CoV-2 worsens in-hospital outcomes.

• Chagas disease patients were observed to have lower C-reactive protein (CRP) levels.

• Given the current circulation of SARS-CoV-2 at high levels and millions of T cruzi-infected individuals living in Brazil, the risk for co-infections substantially increases.

• Further studies are needed to investigate why CRP levels were lower in CD patients. We hypothesized that CD patients might have a lower risk of unregulated inflammatory response to COVID-19, as they already have an active chronic inflammatory and immune response response triggered by T.cruzi infection.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021.

Since the first case of coronavirus disease 19 

February 26 th , 2020, SARS-CoV 2 infection has evolved as a global pandemic. The disease has a wide spectrum of clinical manifestations, ranging from asymptomatic cases to severe pneumonia and acute respiratory distress syndrome. [1, 2] Although the great majority of symptoms are unspecified, mild, flu-like or belonging to respiratory sphere, other organs could be affected, as the cardiovascular system. COVID-19 has been associated with multiple cardiac manifestations, including cardiac arrhythmias, myocardial infarction, acute heart failure and acute fulminant myocarditis. Cardiovascular involvement has shown to be associated with increased mortality. [3, 4] Underlying comorbidities have been widely associated with a worse prognosis for COVID-19 patients, since viral infections could act as triggers for worsening of chronic diseases. [5] [6] [7] Chagas disease (CD) is a multisystemic disorder, potentially affecting, cardiovascular, digestive, and neurological systems. It is the most common cause of infectious cardiomyopathy worldwide, and it may play a role in the clinical prognosis of COVID-19 patients. [8, 9] Although CD is endemic in Latin America, it has been recognized that the disease is now a worldwide concern, as the disease spread with population movements from endemic to non-endemic countries. [10] In Brazil, CD still remains a public health challenge, being one the countries with more absolute number of patients and an annual incidence rate of approximately 0.16 per 100,000

inhabitants/year. [11] Potential interactions between COVID-19 and Chagas cardiomyopathy could be probable, because both conditions share the same immunological pathway. SARS-CoV-2 spike proteins bind to angiotensin-converting enzyme-2 (ACE-2), which is needed to invade the host cell. On the other hand, ACE2 is involved in heart function and the development of hypertension and diabetes mellitus (DM), risk factors frequently observed in patients with chronic Chagas cardiomyopathy. [12, 13] Those patients could have increased levels of ACE2 because of the chronic use of ACE inhibitors and/or angiotensin receptor blockers (ARBs).

Limited information is available regarding the characteristics and outcomes of patients with CD and COVID-19. Therefore, we aim to describe the characteristics, laboratory, and imaging findings, as well as in-hospital outcomes of CD and COVID-19 coinfected patients included in the Brazilian COVID-19 Registry.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) For the present study, patients with previous history of CD recorded in the database were selected. CD diagnosis were retrieved by their own hospital record or self-referred by the patient. Patients were admitted from March 1 to September 30, 2020. At the moment of the analysis 7,018 patients were introduced in the registry, 31 of those were classified as suffering from CD.

Study data were collected by trained hospital staff or interns using Research Electronic Data Capture (REDCap) tools. [16] Medical records were reviewed to collect data on patients' demographic and clinical characteristics, including age, sex, preexisting medical conditions and home medications; COVID-19 symptoms at hospital presentation; clinical assessment upon hospital admission, third and fifth admission days; laboratory, imaging, electrocardiographic data; inpatient medications, treatment and outcomes. Definitions were published elsewhere. [5] Statistical analysis Genetic matching for sex, age, hypertension, DM and hospital was performed in a 4:1 ratio (MatchIt package in R). Sample size of 132 controls was calculated . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.22.21254078 doi: medRxiv preprint considering and expected risk ratio for mortality 2.5 in CD-group, power of 80%, alfaerror probability of 5% for a 4:1 CD/control. Categorical data were presented as absolute numbers and proportions, and continuous variables were expressed as medians and interquartile ranges. The χ 2 and Fisher Exact test were used to compare the distribution of categorical variables, and the Wilcoxon-Mann-Whitney test for continuous variables. Results were considered statistically significant if the two-tailed P-value was < 0.05. All statistical analysis was performed with R software (version 4.0.2).

The study was approved by the National Commission for Research Ethics (CAAE 30350820.5.1001.0008). Individual informed consent was waived owing to the pandemic situation and the use of deidentified data, based on medical chart review only. Patients were from 11 hospitals, with average 382 beds (ranging from 60 to 936 beds). Nine of them (81.8%) were public, 7 (63.6%) were teaching hospitals and 8 (72.7%) were reference centers for COVID-19 treatment.

When comparing CD patients with controls (Table 1) , there were no significant differences in demographic and medical characteristics, except for the prevalence of The median time since from symptom onset to hospital admission was 6 days. Dyspnea and cough (dry or productive) were present in more than one half of patients. There were no differences in the clinical presentation between both groups (Table 2) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ;

Laboratory and imaging findings are presented in Supplementary Table 1 and 2. Median C-reactive protein was lower in CD patients than the controls (55. 5 At admission, diffuse interstitial infiltrate pattern and ground glass opacities were the most prevalent findings in the chest X-ray and chest computer tomography (CT), respectively. No significant differences were found in the frequency of abnormalities and radiological progression in both groups, expect for the frequency of pleural effusion in the follow-up CT, more frequent in CD patients.

Among CD, patients 10 had an EKG performed. Of those, 4 patients had atrial fibrillation and 2 had a pacemaker rhythm, so the proportion of patients with sinus rhythm in controls were significantly higher than in CD patients (68.8% vs 40.0%, p = 0.142) ( Table 3) .

There were no differences regarding the therapeutic strategy among both groups (Table 4) (Table 5 ).

We described a cohort of CD patients infected with SARS-COV-2 and admitted in hospitals belonging to a large Brazilian COVID-19 Registry project. Overall, CD patients had similar clinical characteristics and outcomes to non-CD controls, matched by age, sex, hypertension, DM and hospital, except from a higher prevalence of atrial fibrillation and chronic heart failure, and lower C-reactive protein levels.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Due to the potential cardiac involvement, and the higher procoagulant state, T.cruzi and SARS-COV-2 coinfection has been postulated as condition for myocardial damage, depression of ventricular function, increased arrhythmogenic state, thromboembolism risk, and ultimately a worst prognosis. [17] [18] [19] However, it was only a hypothesis and no previous study has tested it using patient data. Despite the limited number of patients with CD (31) our study refuted did not confirm the hypothesis. We did not find any significant difference or even a trend of worse clinical outcomes in CD patients, even with a higher frequency of atrial fibrillation and heart failure in the CD group.

Current data demonstrates that SARS-CoV-2 infection induces immune dysfunction, widespread endothelial injury, complement-associated coagulopathy and systemic microangiopathy. [20] By the other hand, T. cruzi infection is associated with an upregulated procoagulant activity in plasma. Therefore, it could be expected a greater risk of thromboembolic manifestations. In our cohort the overall thrombosis event was 4.5% (7 out of 155), all of them were in the control group. Noteworthy that, the great majority of patients (91%) were treated with oral anticoagulants because its underlying disease or received any kind of prophylactic heparin when admitted to the hospital, as recommended by national and international guidelines for the management of in-hospital COVID-19 patients. [21, 22] The lower median C-reactive level in CD patients was an unexpected finding.

We hypothesize that CD patients, as they already have an active chronic inflammatory and immune response response triggered by T.cruzi infection, might have a lower risk of unregulated inflammatory response to COVID-19. [23] Therefore, what could have been a factor for worse prognosis, due to a higher frequency of associated heart failure and atrial fibrillation and the CD itself, could be equilibrated by a controlled inflammatory response. This is only a hypothesis, that merits consideration for future studies. If proved correct, it may add to the knowledge of understating how to prevent the unregulated inflammatory response in COVID-19.

It is also interesting to discuss the influence that the use of anticoagulants in full doses may have had on the outcomes of patients with CD and COVID-19. The higher prevalence of atrial fibrillation in those patients may had led to a higher frequency of use of therapeutic dosage anticoagulants (19.3% vs. 10.5%), which did not reach statistical significance due to the sample size. The best strategy to be used -prophylactic or therapeutic heparin doses -in patients with moderate to severe COVID-19 is not yet . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. published, but at least, there is a concern that COVID-19 disease therapeutics could potentially trigger reactivation of CD. This merits further investigation and until definitive evidence is published, it should be a cause of concern in decision making, when prescribing immunosuppressors in these patients.

The fact that the majority of CD patients were admitted to public hospitals (81.8%) is an indicator that CD disproportionally affects people from lower income background. In a previous multivariate analysis, we demonstrated that despite being admitted to public hospitals patients do not have worse prognosis than patients admitted to private ones. [5] This study has limitations. In addition to the retrospective design, subject to the drawbacks of a patient records review, the number of CD was low. However, it is the largest series published to date. Due to the pragmatic study design, laboratory and imaging tests were performed at the discretion of the treating physician. Despite the limited representativity of radiologic, tomographic and electrocardiographic analysis, no patient performed echocardiogram during hospital admission.

Although coinfection by Trypanosoma cruzi and SARS-COV-2 may pose a risk of complications and therefore a worse prognosis, in our series we did not find significant differences in terms of clinical presentation and outcomes of patients with CD compared to controls, despite a higher frequency of chronic heart failure and atrial . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.22.21254078 doi: medRxiv preprint fibrillation at baseline. We observed lower C-reactive protein levels in CD when compared to controls, and this merits further investigation.

We would like to thank the hospitals which are part of this collaboration, for supporting this Project. Especifically for this analysis, we thank the hospitals: Hospital We also thank all the clinical staff at those hospitals, who cared for the patients, and all undergraduate students who helped with data collection. 

The sponsors had no role in study design; data collection, management, analysis, and interpretation; writing the manuscript; and decision to submit it for publication. IM, MSM and MP had full access to all the data in the study and had responsibility for the decision to submit for publication.

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.22.21254078 doi: medRxiv preprint

Data are available upon reasonable request.

The lead authors (MSM, IM and MCP) affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.22.21254078 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.22.21254078 doi: medRxiv preprint

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical, laboratory and imaging features of COVID-19: A systematic review and metaanalysis

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

COVID-19 and the cardiovascular system

Clinical characteristics and outcomes of patients hospitalized with COVID-19 in Brazil: results from the Brazilian COVID-19 Registry

ABC2-SPH risk score for in-hospital mortality in COVID-19 patients: development, external validation and comparison with other available scores

Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score

Chagas disease

Chagas disease: a new worldwide challenge

Chagas disease in Latin America: an epidemiological update based on 2010 estimates

COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression

COVID-19: Implications for People with Chagas Disease. Glob Heart

Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management

Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response

Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

Guidelines for the pharmacological treatment of COVID-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology

22 ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic

The Unsolved Jigsaw Puzzle of the Immune Response in Chagas Disease

Immunosuppression and Chagas disease; experience from a non-endemic country